Aktiesnakken — Februar 2010
-
we don't have the data to answer the questions.... vedr. interaction med xenazyne
-
there is the possibilitiy but we don't have the data..... er det korte svar.
-
"we cannot judge any comparative prices to other drugs"... not fair right now, siden vi lige har fået data.
-
Hatholt, Nordea: Spgm. om positioning i markedet?
-
og spgm. om patientantallet for huntexil
-
Positioneringspgm. er mht. effekt på de forskellige symptomer og hvilke dele af huntington de så vil gå efter... som jeg forstår det.
-
konsensus er omkring 100,000 patienter på verdensbasis..... men det er ikke off. tal..
-
men baseret på mindre patientgruper og extrapoleret.
-
til globalt plan.
-
spgm om adv. event profiles? hvordan er fordeling mht. tid...
-
fordeling er ens.... ingen uregelmæssigheder
-
drop outs pga. adverse events..... were mainly because of regular adverse events.... not drug-related.
-
drug-unrelated er vist det rigtige ord.
-
hugreffe: patentspgm... evt. extention pga. data idag?
-
currently i don't think we can speculate on further patenting... today.
-
Enskilda: partners? how many partners were you in discussion with b4 data? nogen preferred partner?
-
big pharma? andre?
-
specialty pharma?
-
no specific religion to which partner to select...... basalt set, hvem bringer mest værdi til produktet (og til neur)
-
vi vil meget gerne have kontrol og speed.... så hvis der evt. kommer en partner ind er det vigtigt at vi sidder med i førersædet... og
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind